Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

Conference Call Scheduled Today at 4:30pm ET

European Commission Decision on Qutenza(TM) Expected in 1H 2009

Company to Provide Update on FDA review of Qutenza During Conference Call Today

Corporate Highlights:

- CHMP issued positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain

Upcoming 2009 Milestones:

- European Commission decision on MAA for Qutenza anticipated first half of 2009

- European commercial partnership for Qutenza targeted first half of 2009

- FDA PDUFA date of August 16, 2009 for Qutenza NDA to manage pain associated with PHN

SAN MATEO, Calif., May 7 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the first quarter ended March 31, 2009 and provided an update on recent developments.

During the first quarter of 2009, NeurogesX continued to focus on seeking regulatory approvals and on pre-commercialization activities for its lead product candidate Qutenza (formerly NGX-4010). On March 19, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of the marketing authorization application (MAA) for Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The CHMP's recommendation for the MAA, filed under the centralized procedure, is
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 Shimadzu ... chromatography systems, Prominence-i and Nexera-i, adding to the ... Combining excellent functionality, an intuitive operating environment, and ... a more efficient workflow for conventional to ultra-high-speed ... innovative, intuitive and intelligent design so users can ...
(Date:8/19/2014)... -- Research and Markets  has announced the addition of ... Business Report" report to their offering. ... Cells (SOFCs) in US$ Thousands. The report provides separate comprehensive ... Europe , Asia-Pacific , and ... the period 2012 through 2020. Market data and analytics are ...
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the ... industry, recently announced the formation of the company,s Medical ... announce the addition of Dr. William E. Gannon, ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with ... variety of therapeutic areas and set strategic goals for ...
(Date:8/19/2014)... Sales Horizons, a leader in sales ... sales skills training course to help companies develop ... staff spend the majority of their time on client ... or physician practice – providing support and education to ... Sales Horizons believes clinical staff are and should be ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3
... speculate that the Greater Madison area, while a key ... the "critical mass" of talent, innovation, and specialization necessary ... sustained growth. , ,But as area biotech leaders and ... discovery tool provider, Caden Biosciences , to a ...
... Madison, Wis. - The Madison-based Imago Scientific ... to Iowa State University's College of Engineering ... High Throughput Atom-Scale Analysis. , ,The lab will be ... Discovery, which is led by Balaji Narasimhan, an associate ...
... to the future growth and success of the state ... state boasts significant competitive advantages in terms of talent, ... mass needed to compete with our most significant competition ... resources so vital to building and sustaining economic growth. ...
Cached Biology Technology:Caden Biosciences may signal critical mass 2Regional collaboration is key to state's future 2Regional collaboration is key to state's future 3
(Date:8/20/2014)... approximately 3 million infants, a team of scientists across ... Massachusetts Medical School, have shown that newborn screening for ... public health newborn screening programs. Data from 11 newborn ... the Journal of the American Medical Association ... newborns is higher than previously thought and believed to ...
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... U.S. Department of Energy this month awarded a group ... develop bacteria that can turn the methane in natural ... we,re shooting for will have the same fuel characteristics ... professor of chemical engineering and microbiology. "It can be ...
... Innes Centre will publish the first RNA sequence data on the ... will release the data via a website to a system designed ... used to crowdsource expertise during the 2011 E. coli ... able to access the RNA sequence and start to analyse it ...
... University of Illinois at Urbana-Champaign has received a fiveyear, $5.7 ... in corn. These strains have the potential to combat the ... yield. A team at the Institute for Genomic Biology in ... lead the research. "Ozone can cause major damage ...
Cached Biology News:Energy Deptartment funds UW project to turn wasted natural gas into diesel 2Crowdsourcing to kickstart comeback from ash dieback 2University of Illinois receives grant to study ozone resistance in corn 2
Assay Diluent, 10 L...
Assay Diluent Trial Pack, 4 x 100 mL...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
Biology Products: